Conditions Influencing the Interaction of Asialo von Willebrand Factor with Human Platelets – The Effects of External Ionized Calcium Concentration and the Role of Arachidonate Pathway

Marco Cattaneo; J Fraser Mustard; Maria T Canciani; Mary Richardson; Augusto B Federici; Pier Mannuccio Mannucci

doi:10.1055/s-0038-1647045

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1988; 60(02): 280-288
DOI: 10.1055/s-0038-1647045

Original Article

Schattauer GmbH Stuttgart

Conditions Influencing the Interaction of Asialo von Willebrand Factor with Human Platelets – The Effects of External Ionized Calcium Concentration and the Role of Arachidonate Pathway

Marco Cattaneo

^*The A. Bianchi Bonomi Hemophilia and Thrombosis Centre and Institute of Internal Medicine University of Milano and Maggiore Hospital, Milano, Italy and

,

J Fraser Mustard

^**The Dept, of Pathology, McMaster University, Hamilton, Ontario, Canada

,

Maria T Canciani

^*The A. Bianchi Bonomi Hemophilia and Thrombosis Centre and Institute of Internal Medicine University of Milano and Maggiore Hospital, Milano, Italy and

,

Mary Richardson

^**The Dept, of Pathology, McMaster University, Hamilton, Ontario, Canada

,

Augusto B Federici

^*The A. Bianchi Bonomi Hemophilia and Thrombosis Centre and Institute of Internal Medicine University of Milano and Maggiore Hospital, Milano, Italy and

,

Pier Mannuccio Mannucci

^*The A. Bianchi Bonomi Hemophilia and Thrombosis Centre and Institute of Internal Medicine University of Milano and Maggiore Hospital, Milano, Italy and

› Author Affiliations

Abstract

PDF Download

Summary

We have studied the interaction of ASvWf with human platelets in PRP and in suspensions of washed platelets containing either physiological or low external ionized calcium concentration [Ca²⁺]₀. In hirudin-PRP or in washed platelets in 1.5-2 mM CaCl₂, ASvWf up to 50 μg/ml does not induce platelet aggregation or the release reaction. When [Ca²⁺]_c is decreased by addition of citrate to hirudin-PRP or when no CaCl₂ is added to washed platelet suspensions, ASvWf does induce platelet aggregation and the release reaction. In low [Ca²⁺]₀, ASvWf interacts with platelet GPIb to cause primary aggregation of disc-shaped platelets to each other through GPIIb/IIIa, with or without added fibrinogen. This primary platelet aggregation leads to thromboxane A₂ formation and secondary aggregation and the release reaction. With [Ca²⁺]₀ in the physiological range, there is less ASvWf interaction with GPIb, no primary platelet aggregation and no thromboxane A₂ formation. The ASvWf-platelet interaction at physiological [Ca²⁺]₀, however, enhances the platelet response to collagen or epinephrine.

Keywords

Asialo von Willebrand factor - External ionized calcium - Platelet aggregation - Platelet glycoproteins lb and Ilb/IIIa - Arachidonate pathway

PDF (2182 kb)

References

References
1 Zimmerman TS, Ruggeri ZM. von Willebrand's disease. In: Clinics in Hematology Harker LA, Zimmerman TS. (eds) W. B. Saunders Co., Ltd; London: 1983. (; Vol l2). 175-200
2 Weiss HJ, Baumgartner HR, Tschopp TB, Turitto VT, Cohen D. Correction of factor VIII of the impaired platelet adhesion to subendothelium in von Willebrand's disease. Blood 1978; 51: 267-279
3 Weiss HJ, Turitto VT, Baumgartner HR. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear rate-dependent decrease of adhesion in von Willebrand's disease and the Bernard-Soulier syndrome. J Lab Clin Med 1978; 92: 750-764
4 Ruan C, Tobelem G, McMichael AJ, Drouet AJ, Legrand Y, Degos L, Kieffer N, Lee H, Caen JP. Monoclonal antibody to human platelet glycoprotein I. Br J Haematol 1981; 49: 511-519
5 Kao KJ, Pizzo SV, McKee PA. Demonstration and characterization of specific binding sites for factor VUI/von Willebrand factor on human platelets. J Clin Invest 1979; 63: 656-664
6 Coller BS. Platelet von Willebrand factor interactions. In: Platelet Membrane Glycoproteins George JN, Nurden AT, Philips DR. (eds) Plenum Press; New York: 1985: 215-244
7 Ruggeri ZM, Bader R, De Marco L. Glanzmann thrombasthenia: deficient binding of von Willebrand factor to thrombin-stimulated platelets. Proc Natl Acad Sci USA 1982; 79: 6038-6041
8 Ruggeri ZM, De MarcoL, Montgomery RR. Platelets have more than one binding site for von Willebrand factor. J Clin Invest 1983; 72: 1-12
9 Schullek J, Jordan J, Montgomery RR. Interaction of von Willebrand factor with human platelets in the plasma milieu. J Clin Invest 1984; 73: 421-428
10 Gralnick HJ, Williams S, Coller BS. Fibrinogen competes with von Willebrand factor for binding to the glycoprotein Ilb/IIIa complex when platelets are stimulated with thrombin. Blood 1984; 64: 797-800
11 Pietu G, Cherel G, Marguerie G, Meyer D. Inhibition of von Willebrand factor-platelet interaction by fibrinogen. Nature 1984; 308: 648-649
12 De MarcoL, Girolami A, Zimmerman TS, Ruggeri ZM. von Willebrand factor interaction with the glycoprotein Ilb/IIIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J Clin Invest 1986; 77: 1272-1277
13 De MarcoL, Shapiro S. Properties of human asialo-factor VIII. A ristocetin-independent platelet-aggregating agent. J Clin Invest 1981; 68: 321-328
14 Vermylen J, De GaetanoG, Donati MB, Verstraete M. Platelet aggregating activity in neuraminidase-treated human cryoprecipitate: its correlation with factor-VIII related antigen. Br J Haematol 1974; 26: 645-650
15 Vermylen J, Bottecchia D, Szpilman H. Factor VIII and human platelet aggregation. III. Further studies on aggregation of human platelets by neuraminidase-treated human factor VIII. Br J Haematol 1976; 34: 321-330
16 Gralnick HG, Williams SB, Coller BS. Asialo von Willebrand factor interaction with platelets. Interdependance of glycoprotein lb and lib/Ilia for binding and aggregation. J Clin Invest 1985; 75: 19-25
17 De MarcoL, Girolami A, Russell S, Ruggeri ZM. Interaction of asialo von Willebrand factor with glycoprotein lb induces fibrinogen binding to the glycoprotein Ilb/IIIa complex and mediates platelet aggregation. J Clin Invest 1985; 75: 1198-1203
18 Gralnick HJ, Williams SB, MeKeown LP, Rick ME, Maisonneuve P, Jenneau C, Sultan Y. von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor. J Clin Invest 1985; 76: 1522-1529
19 Oreskes I, Hirsch C, Douglas KS, Kupfer S. Measurement of ionized calcium in human plasma with a calcium selective electrode. Clin Chim Acta 1968; 21: 303-313
20 Mustard JF, Perry DW, Kinlough-Rathbone RL, Packham MA. Factors responsible for ADP-induced release reaction of human platelets. Am J Physiol 1975; 228: 1757-1765
21 MacFarlane DE, Walsh PN, Mills DC B, Holmsen H, Day HJ. The role of thrombin in ADP-induced platelet aggregation and release: a critical evaluation. Br J Haematol 1975; 30: 457-463
22 Guccione MA, Packham MA, Kinlough-Rathbone RL, Perry DW, Mustard JF. Reactions of polylysine with human platelets in plasma and in suspensions of washed platelets. Thromb Haemostas 1976; 36: 360-375
23 Kinlough-Rathbone RL, Mustard JF, Packham MA, Perry DW, Reimers HJ, Cazenave JP. Properties of washed human platelets. Thromb Haemostas 1977; 37: 291-308
24 Glusa E, Markwardt F. Adrenaline-induced reactions of human platelets in hurudin plasma. Haemostasis 1980; 9: 188-192
25 Lages B, Weiss HJ. Dependence of human platelet functional responses on divalent cations: aggregation and secretion in heparin- and hirudin-anticoagulated platelet-rich plasma and the effects of chelating agents. Thromb Haemostas 1981; 45: 173-179
26 Molnar J, Lorand L. Studies in apyrases. Arch Biochem Biophys 1961; 93: 353-363
27 Lawrie JS, Ross J, Kemp GD. Purification of fibrinogen and the separation of its degradation products in the presence of calcium ions. Biochem Soc Trans 1974; 7: 693-694
28 Kinlough-Rathbone RL, Packham MA, Mustard JF. The effect of prostaglandin E₁ on platelet function in vitro and in vivo. Br J Haematol 1970; 19: 559-571
29 Cazenave JP, Packham MA, Mustard JF. Adherence of platelets to a collagen-coated surface: development of a quantitative method. J Lab Clin Med 1973; 82: 978-990
30 Mustard JF, Perry DW, Ardlie WG, Pakham MA. Preparation of suspensions of washed platelets from humans. Br J Haematol 1972; 22: 193-204
31 Costa JL, Murphy DL. Platelet 5HT uptake and release stopped rapidly by formaldehyde. Nature 1975; 255: 407-409
32 Newman J, Johnson AJ, Karpatkin MH, Puszkin S. Methods for the production of clinically effective intermediate- and high-purity factor- VIII concentrates. Br J Haematol 1971; 21: 1-20
33 Switzer ME, McKee PA. Studies on human antihemophilic factor. Evidence for a covalently linked subunit structure. J Clin Invest 1976; 57: 925-937
34 Ruggeri ZM, Mannucci PM, Bader R, Barbui T. Factor VIII related properties in platelets from patients with von Willebrand's disease. J Lab Clin Med 1978; 91: 132-140
35 Ruggeri ZM, Zimmerman TS. The complex multimeric,composition of factor VUI/von Willebrand factor. Blood 1981; 57: 1140-1143
36 Warren L. The thiobarbituric acid assay of sialic acids. J Biol Chem 1959; 234: 1971-1975
37 Lowry OH, Rosemberg NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-275
38 Federici AB, Elder JH, De MarcoL, Ruggeri ZM, Zimmerman TS. Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation. J Clin Invest 1984; 74: 2049-2055
39 McFarlane AS. Efficient trace labelling of proteins with iodine. Nature 1958; 182: 53
40 Lee RM K W, Garfield RE, Forest JB, Daniel EE. The effects of fixation, dehydration and critical point drying on the size of cultured smooth muscle cells. In: Scanning Electron Microscopy SEM Inc., AMF O'Haze, IL; 1979: 439-448
41 Groves HM, Kinlough-Rathbone RL, Richardson M, Moore S, Mustard JF. Platelet interaction with damaged rabbit aorta. Lab Invest 1979; 40: 194-200
42 Kinlough-Rathbone RL, Mustard JF, Packham MA, Harfenist EJ. Factors influencing the deaggregation of chymotrypsin-treated human platelets aggregated by fibrinogen. Thromb Haemostas 1983; 49: 196-198
43 Williams SB, MeKeown LP, Gralnick HR. Asialo von Willebrand factor binding to and aggregation of platelets: Effects of inhibitors of platelet metabolism and function. J Lab Clin Med 1987; 109: 560-565
44 Cattaneo M, Kinlough-Rathbone RL, Lecchi A, Bevilacqua C, Packham MA, Mustard JF. Fibrinogen-independent aggregation and deaggregation of human platelets: studies in two afibrinogenemic patients. Blood 1987; 70: 293-300
45 Soria J, Soria C, Borg JV, Mirshashi M, Pignet H, Tron P, Fessard C, Caen JP. Platelet aggregation occurs in congenital afibrinogenemia despite the absence of fibrinogen or its fragments in plasma, and platelets, as demonstrated by immunoenzymology. Br J Haematol 1985; 60: 503-514
46 Shattil SJ, Brass LF. The interaction of extracellular calcium with the platelet membrane glycoprotein Ilb-IIIa complex. Nouv Rev Fr Haematol 1985; 27: 211-217
47 DeMarco L, Mazzuccato M, Del Ben MG, Budde V, Federici AB, Girolami A, Ruggeri ZM. Type IIB von Willebrand factor with normal sialic acid content induces platelet aggregation in the absence of ristocetin. Role of, platelet activating, fibrinogen and two distinct membrane receptors. J Clin Invest 1987; 80: 475-482
48 Morell AG, Gregoradis G, Scheinberg IH, Hickman J, Ashwell G. The role of sialic acid in determining the survival of glycoproteins in the circulation. J Biol Chem 1971; 246: 1461-1467